Carcinogenesis Advance Access originally published online on April 13, 2007
Carcinogenesis 2007 28(8):1665-1671; doi:10.1093/carcin/bgm085
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Functional characterization of single-nucleotide polymorphisms and haplotypes of human N-acetyltransferase 2
Department of Pharmacology and Toxicology and James Graham Brown Cancer Center, University of Louisville School of Medicine, Louisville, KY 40292, USA
* To whom correspondence should be addressed. Tel: +1 502 852 5141; Fax +1 502 852 7868;Email: d.hein{at}louisville.edu
Human N-acetyltransferase 2 (NAT2) is polymorphic in humans and may associate with cancer risk by modifying individual susceptibility to cancers from carcinogen exposure. Since molecular epidemiological studies investigating these associations usually include determining NAT2 single-nucleotide polymorphisms (SNPs), haplotypes or genotypes, their conclusions can be compromised by the uncertainty of genotype–phenotype relationships. We characterized NAT2 SNPs and haplotypes by cloning and expressing recombinant NAT2 allozymes in mammalian cells. The reference and variant recombinant NAT2 allozymes were characterized for arylamine N-acetylation and O-acetylation of N-hydroxy-arylamines. SNPs and haplotypes that conferred reduced enzymatic activity did so by reducing NAT2 protein without changing NAT2 mRNA levels. Among SNPs that reduced catalytic activity, G191A (R64Q), G590A (R197Q) and G857A (G286E) reduced protein half-life but T341C (I114T), G499A (E167K) and A411T (L137F) did not. G857A (G286E) and the major haplotype possessing this SNP (NAT2*7B) altered the affinity to both substrate and cofactor acetyl coenzyme A, resulting in reduced catalytic activity toward some substrates but not others. Our results suggest that coding region SNPs confer slow acetylator phenotype by multiple mechanisms that also may vary with arylamine exposures.
Abbreviations: ABP, 4-aminobiphenyl; AcCoA, acetyl coenzyme A; HCA, heterocyclic amine; HPLC, high-performance liquid chromatography; NAT2, N-acetyltransferase 2; PhIP, 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine; SMZ, sulfamethazine; SNP, single-nucleotide polymorphism
Received February 9, 2007; revised April 3, 2007; accepted April 3, 2007.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
A. Agudo, M. Peluso, N. Sala, G. Capella, A. Munnia, S. Piro, F. Marin, R. Ibanez, P. Amiano, M.J. Tormo, et al. Aromatic DNA adducts and polymorphisms in metabolic genes in healthy adults: findings from the EPIC-Spain cohort Carcinogenesis, June 1, 2009; 30(6): 968 - 976. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Jiao, M. A. Doll, D. W. Hein, M. L. Bondy, M. M. Hassan, J. E. Hixson, J. L. Abbruzzese, and D. Li Haplotype of N-Acetyltransferase 1 and 2 and Risk of Pancreatic Cancer Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2379 - 2386. [Abstract] [Full Text] [PDF] |
||||

